脑脊液与PET的β-淀粉样蛋白不一致与5年后tau负荷的关联
本研究基于ADNI队列730例无痴呆参与者,探讨基线Aβ脑脊液/PET状态不一致与5年后tau病理出现的关系。结果显示CSF+/PET-组5年后tau PET摄取与CSF-/PET-组无差异,但显著低于CSF+/PET+组;CSF+/PET-组仅3%转为tau阳性。结论认为CSF和PET均可检测的Aβ负荷似乎先于大量tau沉积,CSF+/PET-组预后明显更好。
要点
- CSF+/PET-组5年后tau PET摄取与CSF-/PET-组无差异,显著低于CSF+/PET+组。
- CSF+/PET-组仅3%转为tau阳性,而33%进展为Aβ CSF+/PET+。
- CSF和PET均可检测的Aβ负荷似乎先于大量tau沉积。
核心结论
- CSF和PET均可检测的Aβ负荷似乎先于大量tau沉积,CSF+/PET-组预后明显更好。
研究设计与样本
- 纳入730例ADNI无痴呆参与者(282例认知正常,448例轻度认知障碍),基线均有[18F]florbetapir PET和CSF Aβ42。
- 基线用既定截断值判定Aβ CSF/PET状态,纵向随访[18F]florbetapir PET、CSF (p)tau、认知和[18F]flortaucipir PET。
- 采用线性混合模型分析Aβ CSF/PET状态与CSF或PET所测tau病理的关联。
主要发现
- CSF+/PET+组(n=318)基线CSF (p)tau升高且认知表现更差,CSF+/PET-组(n=80)总体与CSF-/PET-组(n=306)相似。
- 基线5年后,CSF+/PET-组[18F]flortaucipir PET摄取(1.20±0.13)与CSF-/PET-组(1.18±0.08,p=0.69)无差异,但显著低于CSF+/PET+组(1.48±0.44,p<0.001)。
- CSF+/PET-参与者中21/64(33%)进展为Aβ CSF+/PET+,仅1例(3%,差异p<0.05)基于[18F]flortaucipir PET转为tau阳性。
临床怎么用
- 对Aβ CSF+/PET-的无痴呆患者,可提示其5年内tau沉积风险较低、预后较好。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To investigate the association between discordant β-amyloid (Aβ) PET and CSF biomarkers at baseline and the emergence of tau pathology 5 years later. METHODS: We included 730 Alzheimer's Disease Neuroimaging Initiative (ADNI) participants without dementia (282 cognitively normal, 448 mild cognitive impairment) with baseline [18F]florbetapir PET and CSF Aβ42 available. Aβ CSF/PET status was determined at baseline using established cutoffs. Longitudinal data were available for [18F]florbetapir (Aβ) PET (baseline to 4.3 ± 1.9 years), CSF (p)tau (baseline to 2.0 ± 0.1 years), cognition (baseline to 4.3 ± 2.0 years), and [18F]flortaucipir (tau) PET (measured 5.2 ± 1.2 years after baseline to 1.6 ± 0.7 years later). We used linear mixed modeling to study the association between Aβ CSF/PET status and tau pathology measured in CSF or using PET. We calculated the proportion of CSF+/PET- participants who during follow-up (1) progressed to Aβ CSF+/PET+ or (2) became tau-positive based on [18F]flortaucipir PET. RESULTS: Aβ CSF+/PET+ (n = 318) participants had elevated CSF (p)tau levels and worse cognitive performance at baseline, while CSF+/PET- (n = 80) participants were overall similar to the CSF-/PET- (N = 306) group. Five years after baseline, [18F]flortaucipir PET uptake in the CSF+/PET- group (1.20 ± 0.13) did not differ from CSF-/PET- (1.18 ± 0.08, p = 0.69), but was substantially lower than CSF+/PET+ (1.48 ± 0.44, p < 0.001). Of the CSF+/PET- participants, 21/64 (33%) progressed to Aβ CSF+/PET+, whereas only one (3%, difference p < 0.05) became tau-positive based on [18F]flortaucipir PET. CONCLUSIONS: Aβ load detectable by both CSF and PET seems to precede substantial tau deposition. Compared to participants with abnormal Aβ levels on both PET and CSF, the CSF+/PET- group has a distinctly better prognosis.
引用
- Reimand J, Collij L, Scheltens P, et al. Association of amyloid-β CSF/PET discordance and tau load 5 years later. Neurology. 2020. PMID: 32913020. doi:10.1212/WNL.0000000000010739
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。